Responses
Inflammatory bowel disease
Evaluation of amnion-derived mesenchymal stem cells for treatment-resistant moderate Crohn’s disease: study protocol for a phase I/II, dual-centre, open-label, uncontrolled, dose–response trial
Compose a Response to This Article
Other responses
No responses have been published for this article.